We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Dyne Therapeutics Inc | NASDAQ:DYN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.19% | 26.00 | 14.20 | 26.75 | 26.48 | 25.07 | 25.96 | 538,840 | 05:00:08 |
From May 2023 to May 2024
By Sabela Ojea
Dyne Therapeutics said the U.S. Food and Drug Administration granted orphan drug designation to its DYNE-101 treatment, which targets the multisystem disorder Myotonic Dystrophy Type 1.
The biotechnology company on Wednesday said that DYNE-101 is being evaluated in the Phase 1/2 global achieve clinical trial with initial data on safety expected for the second half of the year.
The orphan drug designation is granted to drugs or biologics intended for treatment, prevention or diagnosis of a rare disease that affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 20, 2023 16:36 ET (20:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Dyne Therapeutics Chart |
1 Month Dyne Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
